Gastrointestinal Imaging

Which Imaging Study Is Best for Staging a Pancreatic Neuroendocrine Tumor?

·
Which Imaging Study Is Best for Staging a Pancreatic Neuroendocrine Tumor?

A 58-year-old patient presents to your clinic after an endoscopic ultrasound with fine-needle aspiration confirmed a well-differentiated neuroendocrine tumor in the tail of the pancreas. The finding was incidental, discovered during a workup for unrelated symptoms. Now, the critical question is staging. Before the multidisciplinary tumor board can recommend surgery, systemic therapy, or another approach, you need to determine the extent of the disease. What is the optimal initial imaging study to evaluate for metastatic disease in this adult with a newly diagnosed pancreatic neuroendocrine tumor (pNET)?

This clinical workflow guide focuses on this specific decision point. Based on the American College of Radiology (ACR) Appropriateness Criteria, the recommended initial study for this scenario is MRI abdomen and pelvis without and with IV contrast, which is rated Usually Appropriate.

Who Fits This Clinical Scenario for pNET Staging?

This guidance is intended for clinicians ordering initial staging imaging for an adult patient with a newly diagnosed, pathologically confirmed, or highly suspected pancreatic neuroendocrine tumor. The primary clinical question is the evaluation for distant metastatic disease to establish a baseline stage, which is fundamental for determining the overall treatment strategy. This scenario assumes the patient has not yet undergone definitive treatment for their pNET.

This workflow is not appropriate for several related but distinct clinical situations:

  • Purely Local Staging: If the primary goal is to assess the local extent of the tumor—such as invasion into the superior mesenteric artery or portal vein to determine surgical resectability—the imaging choice may differ. That specific question is addressed in the ACR variant for local staging of pancreatic neuroendocrine tumor.
  • Post-Surgical Surveillance: This guidance does not apply to asymptomatic patients undergoing routine follow-up imaging after a complete surgical resection. That falls under the surveillance scenario, imaging after surgical resection, no suspected or known recurrence.
  • Follow-up After Treatment: Patients with known metastatic disease who are being monitored after systemic therapy, liver-directed therapy, or peptide receptor radionuclide therapy (PRRT) represent a different clinical question covered by separate follow-up scenarios.

Correctly identifying your patient’s scenario is crucial for selecting the most appropriate and value-driven imaging test.

What Are You Evaluating When Staging a Pancreatic Neuroendocrine Tumor?

When you order a staging study for a pNET, you are primarily searching for evidence of distant disease, as its presence or absence fundamentally alters prognosis and management. While the study will also provide high-resolution detail of the primary tumor, the key targets for metastatic evaluation include several specific locations.

Liver Metastases: This is the most common site of distant spread for pancreatic neuroendocrine tumors. pNET liver metastases are typically hypervascular, meaning they have a rich blood supply. This characteristic makes them enhance avidly during the arterial phase of contrast-enhanced imaging, a key feature that high-quality cross-sectional imaging is designed to detect. Identifying the number, size, and location of liver metastases is critical for staging and for planning potential liver-directed therapies.

Lymph Node Metastases: The second key objective is to identify both regional (peripancreatic) and distant (e.g., retroperitoneal, mesenteric) lymph node involvement. Nodal status is a core component of the formal TNM staging system and has significant prognostic implications.

Bone Metastases: While less common than liver involvement, bone is another potential site for pNET metastases. Staging studies of the abdomen and pelvis will include the lumbar spine and pelvic bones, but dedicated whole-body functional imaging may be required if there is a high clinical suspicion of osseous disease.

Primary Tumor Characterization: The staging study also serves to better delineate the primary pancreatic tumor itself. It provides essential information on tumor size, enhancement characteristics, and its relationship to adjacent organs and major blood vessels, which complements dedicated local staging evaluations.

Why Is MRI of the Abdomen and Pelvis the Recommended Staging Study?

For the initial evaluation of metastatic disease in an adult with a pNET, the ACR designates MRI abdomen and pelvis without and with IV contrast as Usually Appropriate. This recommendation is based on the modality’s excellent diagnostic capabilities for the most common sites of disease, balanced against its safety profile.

The primary advantage of MRI is its superior soft-tissue contrast resolution, which is particularly valuable for detecting and characterizing liver lesions. The hypervascular nature of most pNET metastases makes them conspicuous on dynamic, multiphase contrast-enhanced MRI sequences. This allows for high sensitivity in identifying even small metastatic deposits that could be missed on other studies.

Several other imaging studies are also rated for this scenario, and understanding their roles is key:

  • CT abdomen and pelvis with IV contrast: This is also rated Usually Appropriate and is an excellent alternative, especially if MRI is unavailable, contraindicated (e.g., incompatible implanted device), or not tolerated by the patient. A multiphase CT can also effectively demonstrate hypervascular liver metastases. However, MRI is often considered to have a slight edge in differentiating small metastases from other benign liver lesions.
  • DOTATATE PET/CT skull base to mid-thigh: Also rated Usually Appropriate, this is a powerful functional imaging study. It uses a radiotracer that binds to somatostatin receptors (SSTRs), which are overexpressed on the surface of most well-differentiated pNET cells. It provides whole-body imaging and is exceptionally sensitive for identifying SSTR-positive disease in lymph nodes, liver, bone, and other unexpected locations. Often, both an anatomic study (MRI or CT) and a functional study (DOTATATE PET/CT) are performed as part of a complete initial staging workup. The choice often depends on institutional protocols and the need to confirm SSTR avidity to guide potential future therapy with PRRT.
  • Endoscopic Ultrasound (EUS): This is rated Usually not appropriate for this specific scenario. While EUS is a premier tool for detecting and biopsying the primary pancreatic tumor and assessing local invasion (T-stage), it cannot evaluate for distant metastatic disease in the liver or other organs. Its role is in diagnosis and local staging, not the systemic staging question addressed here.

A significant advantage of MRI is the absence of ionizing radiation (Adult RRL: O 0 mSv). This is an important consideration for pNET patients, who are often diagnosed at a younger age and may require numerous imaging studies over a long period of surveillance. In contrast, both CT and PET/CT involve radiation exposure (Adult RRL: ☢☢☢ 1-10 mSv or higher).

Ordering Pearl: When ordering the MRI, specify a “multiphase liver protocol” or “pancreas protocol” to ensure the radiologist acquires images during the late arterial, portal venous, and delayed phases after contrast administration. This is critical for maximizing the conspicuity of hypervascular metastases.

What’s Next After MRI of the Abdomen and Pelvis? Downstream Workflow

The results of the staging MRI will direct the subsequent clinical pathway and discussions at the multidisciplinary tumor board. The workflow typically branches based on the findings.

  • If the study is positive for metastatic disease: The most common finding would be liver metastases. The report will detail the number, size, and location of these lesions. This confirms Stage IV disease. The next step is typically a multidisciplinary discussion involving medical oncology, surgery, interventional radiology, and nuclear medicine. A DOTATATE PET/CT is often performed, if not already done, to confirm SSTR expression and screen the rest of the body for disease. This information guides decisions between systemic therapy (e.g., somatostatin analogs, targeted therapy), liver-directed therapy (e.g., embolization, ablation), or PRRT.
  • If the study is negative for metastatic disease: If the MRI shows a tumor confined to the pancreas without evidence of distant spread, the patient is considered to have localized disease. The focus then shifts to assessing resectability. This often involves a detailed review of the primary tumor’s relationship to key blood vessels. The patient would be evaluated for surgical resection, which offers the best chance for a cure. The next step is typically a surgical consultation.
  • If the study is indeterminate: Occasionally, the MRI may identify small, nonspecific lesions in the liver or elsewhere that are too small to characterize definitively. In this situation, the next step may be a short-interval follow-up MRI to assess for stability or growth, or proceeding to a DOTATATE PET/CT, which can help clarify if these indeterminate lesions are SSTR-avid and therefore likely related to the pNET.

Pitfalls to Avoid (and When to Get Help)

When ordering staging imaging for a pancreatic neuroendocrine tumor, be mindful of these common pitfalls to ensure an accurate and efficient workup:

  • Ordering a non-contrast study: A CT or MRI of the abdomen without IV contrast is rated Usually not appropriate for this indication. The hypervascularity of pNET metastases is their defining feature, and they may be invisible without the use of IV contrast.
  • Using the wrong modality for the question: Do not order an endoscopic ultrasound (EUS) to look for liver metastases. EUS is for local evaluation; cross-sectional imaging (MRI/CT) or functional imaging (PET/CT) is required for systemic staging.
  • Misinterpreting “negative” PET/CT: Remember that not all pNETs, particularly poorly differentiated or high-grade tumors, express somatostatin receptors. A negative DOTATATE PET/CT does not definitively rule out metastatic disease. In such cases, an FDG-PET/CT (May be appropriate) may be more informative.
  • Forgetting the chest: While MRI of the abdomen and pelvis is the primary recommendation, pNETs can metastasize to the lungs. A baseline non-contrast chest CT is often performed as part of the complete staging workup, though CT chest abdomen pelvis with IV contrast is also a Usually Appropriate option that covers all bases in one scan.

If the imaging findings are complex, equivocal, or discordant with the clinical picture, escalate by discussing the case directly with the reporting radiologist or presenting it at a multidisciplinary tumor board.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to imaging pancreatic neuroendocrine tumors, from local staging to long-term surveillance, please consult the parent topic article. Additional tools can help you apply these guidelines in your practice.

Frequently Asked Questions

Why is MRI preferred over CT for initial pNET staging if both are ‘Usually Appropriate’?

While both are excellent options, MRI is often preferred due to its superior soft-tissue contrast, which can provide a slight advantage in detecting and characterizing small liver metastases. A key benefit is its lack of ionizing radiation, which is important for patients who will likely need many follow-up scans over their lifetime. However, multiphase CT is a very strong and often more accessible alternative.

Should I order a DOTATATE PET/CT instead of an MRI for initial staging?

A DOTATATE PET/CT is also rated ‘Usually Appropriate’ and is a critical part of the workup. It provides functional information about somatostatin receptor expression and whole-body assessment. Many institutions perform both an anatomic study (MRI or CT) and a functional study (DOTATATE PET/CT) for comprehensive initial staging. The MRI/CT provides superior anatomic detail of the liver and pancreas, while the PET/CT assesses whole-body SSTR-avidity, which is crucial for planning potential peptide receptor radionuclide therapy (PRRT).

What if my patient has a contraindication to MRI, like a pacemaker?

If a patient cannot undergo an MRI, a multiphase CT of the abdomen and pelvis with IV contrast is the appropriate alternative. It is also rated ‘Usually Appropriate’ by the ACR for this exact scenario and is highly effective at detecting the hypervascular metastases typical of pancreatic neuroendocrine tumors.

Does this staging MRI of the abdomen and pelvis adequately evaluate for bone metastases?

The MRI will visualize the bones of the lumbar spine and pelvis, but it is not a whole-body survey for bone metastases. If there is a high clinical suspicion for bone involvement (e.g., bone pain, elevated alkaline phosphatase), a DOTATATE PET/CT is far more sensitive for detecting osseous metastases from a well-differentiated pNET.

Is an MRI of the abdomen sufficient, or do I need to include the pelvis?

Including the pelvis is standard for oncologic staging. While the liver and regional lymph nodes are the most common sites of spread, metastatic disease can occur in pelvic lymph nodes or the pelvic bones. An MRI of the abdomen and pelvis provides a more complete initial assessment of potential disease spread below the aortic bifurcation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026